** Shares of drug developer HCW Biologics HCWB.O rise 252% to 97 cents
** HCWB says it received U.S. FDA's clearance to start clinical trial for treatment of moderate-to-severe alopecia areata, which is an autoimmune disease that causes sudden hair loss
** HCWB says drug HCW9302 is protein therapy that helps reduce inflammation and promote hair growth
** Co says if trial is successful, HCW9302 may also be used to treat other diseases, including skin conditions, arthritis, and diabetes
** More than 154 mln shares traded, 578x their 25-day moving average
** HCWB shares fell 62.5% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.